{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:51:52Z","timestamp":1781823112992,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Leiden University Fund, Fonds Hoogenboom Beck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>NF2<\/jats:italic>\n                    -Related Schwannomatosis (\n                    <jats:italic>NF2<\/jats:italic>\n                    -SWN) is a rare tumor predisposition syndrome characterized by heterogeneous clinical manifestations that substantially impact quality of life (QOL). In this diverse patient population, a disease-specific QOL instrument is essential for both research and clinical decision-making. Insight into factors associated with QOL may further facilitate the tailoring of management strategies to individual patient needs. This study aimed to validate the Dutch version of the\n                    <jats:italic>NF2<\/jats:italic>\n                    Impact on Quality of Life questionnaire (NFTI-QOL) and to identify factors associated with QOL in Dutch patients with\n                    <jats:italic>NF2<\/jats:italic>\n                    . Following forward\u2011 and backward\u2011translation, the NFTI-QOL was administered to\n                    <jats:italic>NF2<\/jats:italic>\n                    -SWN patients alongside the SF\u201136, EQ\u20115D and PANQOL. The NFTI-QOL was repeated after one week. Demographic and clinical data were extracted from medical records. To provide clinical context, questionnaires were also administered to patients with sporadic vestibular schwannoma (sVS). 64\n                    <jats:italic>NF2<\/jats:italic>\n                    -SWN and 51 sVS patients completed the questionnaires. The NFTI-QOL demonstrated good validity and reliability. In multivariate linear regression, dizziness (\u03b2\u2009=\u20092.533,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.027) and facial weakness (\u03b2\u2009=\u20094.064,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.008) were significantly associated with QOL, whereas hearing complaints were not. Surprisingly, overall QOL did not differ between\n                    <jats:italic>NF2<\/jats:italic>\n                    -SWN and sVS patients, whereas patients with sVS even reported poorer hearing-related QOL. The Dutch NFTI-QOL is a reliable instrument for assessing QOL in\n                    <jats:italic>NF2-SWN<\/jats:italic>\n                    patients. Dizziness and facial weakness were associated with lower QOL, while hearing problems were not.\n                  <\/jats:p>","DOI":"10.1007\/s10689-026-00581-0","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:01:12Z","timestamp":1781776872000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Determinants of the quality of life of patients with NF2-related schwannomatosis and validation of the Dutch NFTI-QOL questionnaire"],"prefix":"10.1007","volume":"25","author":[{"given":"Annemijn L.","family":"Tops","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorine","family":"Goemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmelien","family":"Aten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine E.","family":"Schopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radboud W.","family":"Koot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen C.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik F.","family":"Hensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"1","key":"581_CR1","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13023-023-02911-2","volume":"18","author":"TJ Lee","year":"2023","unstructured":"Lee TJ, Chopra M, Kim RH, Parkin PC, Barnett-Tapia C (2023) Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis 18(1):292. https:\/\/doi.org\/10.1186\/s13023-023-02911-2","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"581_CR2","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","volume":"24","author":"SR Plotkin","year":"2022","unstructured":"Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO et al (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 24(9):1967\u20131977. https:\/\/doi.org\/10.1016\/j.gim.2022.05.007","journal-title":"Genet Med"},{"key":"581_CR3","unstructured":"Evans DG (1993) NF2-related schwannomatosis. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A (ed), GeneReviews((R)), Seattle"},{"issue":"4","key":"581_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00401-019-02029-5","volume":"139","author":"S Coy","year":"2020","unstructured":"Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S (2020) An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol 139(4):643\u2013665. https:\/\/doi.org\/10.1007\/s00401-019-02029-5","journal-title":"Acta Neuropathol"},{"issue":"2","key":"581_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1055\/s-0036-1579766","volume":"5","author":"JL Kresak","year":"2016","unstructured":"Kresak JL, Walsh M (2016) Neurofibromatosis: a review of NF1, NF2, and schwannomatosis. J Pediatr Genet 5(2):98\u2013104. https:\/\/doi.org\/10.1055\/s-0036-1579766","journal-title":"J Pediatr Genet"},{"issue":"4","key":"581_CR6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/0194599815573002","volume":"153","author":"MK Cosetti","year":"2015","unstructured":"Cosetti MK, Golfinos JG, Roland JT Jr (2015) Quality of life (QoL) assessment in patients with neurofibromatosis Type 2 (NF2). Otolaryngol Head Neck Surg 153(4):599\u2013605. https:\/\/doi.org\/10.1177\/0194599815573002","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"581_CR7","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1212\/CPJ.0000000000000648","volume":"9","author":"A Shukla","year":"2019","unstructured":"Shukla A, Hsu FC, Slobogean B, Langmead S, Lu Y, Blakeley JO et al (2019) Association between patient-reported outcomes and objective disease indices in people with NF2. Neurol Clin Pract 9(4):322\u2013329. https:\/\/doi.org\/10.1212\/CPJ.0000000000000648","journal-title":"Neurol Clin Pract"},{"issue":"10","key":"581_CR8","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/0277-9536(95)00112-k","volume":"41","author":"Whoqol Group","year":"1995","unstructured":"Whoqol Group (1995) The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 41(10):1403\u20131409. https:\/\/doi.org\/10.1016\/0277-9536(95)00112-k","journal-title":"Soc Sci Med"},{"issue":"7 Suppl 1","key":"581_CR9","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1212\/WNL.0000000000012421","volume":"97","author":"PL Wolters","year":"2021","unstructured":"Wolters PL, Vranceanu AM, Thompson HL, Martin S, Merker VL, Baldwin A et al (2021) Current recommendations for patient-reported outcome measures assessing domains of quality of life in neurofibromatosis clinical trials. Neurology 97(7 Suppl 1):S50\u2013S63. https:\/\/doi.org\/10.1212\/WNL.0000000000012421","journal-title":"Neurology"},{"issue":"2","key":"581_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/s-0032-1301396","volume":"73","author":"RE Hornigold","year":"2012","unstructured":"Hornigold RE, Golding JF, Leschziner G, Obholzer R, Gleeson MJ, Thomas N et al (2012) The NFTI-QOL: a disease-specific quality of life questionnaire for neurofibromatosis 2. J Neurol Surg B Skull Base 73(2):104\u2013111. https:\/\/doi.org\/10.1055\/s-0032-1301396","journal-title":"J Neurol Surg B Skull Base"},{"issue":"1","key":"581_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13023-022-02607-z","volume":"18","author":"AC Lawson McLean","year":"2023","unstructured":"Lawson McLean AC, Freier A, Lawson McLean A, Kruse J, Rosahl S (2023) The German version of the neurofibromatosis 2 impact on quality of life questionnaire correlates with severity of depression and physician-reported disease severity. Orphanet J Rare Dis 18(1):3. https:\/\/doi.org\/10.1186\/s13023-022-02607-z","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 1","key":"581_CR12","doi-asserted-by":"publisher","first-page":"i141","DOI":"10.1093\/noajnl\/vdaa003","volume":"2","author":"G Hamoy-Jimenez","year":"2020","unstructured":"Hamoy-Jimenez G, Kim R, Suppiah S, Zadeh G, Bril V, Barnett C (2020) Quality of life in patients with neurofibromatosis type 1 and 2 in Canada. Neurooncol Adv 2(Suppl 1):i141\u2013i149. https:\/\/doi.org\/10.1093\/noajnl\/vdaa003","journal-title":"Neurooncol Adv"},{"key":"581_CR13","doi-asserted-by":"crossref","unstructured":"de Vet HCW, Terwee CB, Mokkink LB, Knol DL (2011) Measurement in medicine\u2014a practical guide. U.S.A., Cambridge University Press, New York, New York","DOI":"10.1017\/CBO9780511996214"},{"key":"581_CR14","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.2147\/JMDH.S419714","volume":"17","author":"P Cruchinho","year":"2024","unstructured":"Cruchinho P, L\u00f3pez-Franco MD, Capelas ML, Almeida S, Bennett PM, Miranda da Silva M, et al. (2024) Translation, Cross-Cultural Adaptation, and Validation of Measurement Instruments: A Practical Guideline for Novice Researchers. J Multidiscip Healthc. 17:2701\u201328. https:\/\/doi.org\/10.2147\/JMDH.S419714","journal-title":"J Multidiscip Healthc."},{"key":"581_CR15","unstructured":"Castor EDC. Castor electronic data capture 2019 [27 Aug. 2019]. Available from: https:\/\/castoredc.com."},{"key":"581_CR16","doi-asserted-by":"crossref","unstructured":"Ware JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. (0025\u20137079 (Print))","DOI":"10.1037\/t06708-000"},{"issue":"3","key":"581_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G (1990) EuroQol\u2013a new facility for the measurement of health-related quality of life. Health Policy 16(3):199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9","journal-title":"Health Policy"},{"issue":"8","key":"581_CR18","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/lary.20988","volume":"120","author":"BT Shaffer","year":"2010","unstructured":"Shaffer BT, Cohen MS, Bigelow DC, Ruckenstein MJ (2010) Validation of a disease-specific quality-of-life instrument for acoustic neuroma: the Penn acoustic neuroma quality-of-life scale. Laryngoscope 120(8):1646\u20131654. https:\/\/doi.org\/10.1002\/lary.20988","journal-title":"Laryngoscope"},{"issue":"11","key":"581_CR19","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/s0895-4356(98)00097-3","volume":"51","author":"NK Aaronson","year":"1998","unstructured":"Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te Velde A, Verrips E (1998) Translation, validation, and norming of the Dutch language version of the SF-36 health survey in community and chronic disease populations. J Clin Epidemiol 51(11):1055\u20131068. https:\/\/doi.org\/10.1016\/s0895-4356(98)00097-3","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"581_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","volume":"19","author":"MM Versteegh","year":"2016","unstructured":"Versteegh MM, Vermeulen KM, Evers SMAA, de Wit GA, Prenger R, Stolk EA (2016) Dutch tariff for the five-level version of EQ-5D. Value Health 19(4):343\u2013352. https:\/\/doi.org\/10.1016\/j.jval.2016.01.003","journal-title":"Value Health"},{"issue":"5","key":"581_CR21","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/MAO.0b013e31828bb2bb","volume":"34","author":"BM van Leeuwen","year":"2013","unstructured":"van Leeuwen BM, Herruer JM, Putter H, Jansen JC, van der Mey AG, Kaptein AA (2013) Validating the Penn acoustic neuroma quality of life scale in a sample of Dutch patients recently diagnosed with vestibular schwannoma. Otol Neurotol 34(5):952\u2013957. https:\/\/doi.org\/10.1097\/MAO.0b013e31828bb2bb","journal-title":"Otol Neurotol"},{"issue":"5","key":"581_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1177\/0194599812458401","volume":"147","author":"RK Gurgel","year":"2012","unstructured":"Gurgel RK, Jackler RK, Dobie RA, Popelka GR (2012) A new standardized format for reporting hearing outcome in clinical trials. Otolaryngol Head Neck Surg 147(5):803\u2013807. https:\/\/doi.org\/10.1177\/0194599812458401","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"1","key":"581_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/0194599812437156","volume":"147","author":"RK Gurgel","year":"2012","unstructured":"Gurgel RK, Popelka GR, Oghalai JS, Blevins NH, Chang KW, Jackler RK (2012) Is it valid to calculate the 3-kilohertz threshold by averaging 2 and 4 kilohertz? Otolaryngol Head Neck Surg 147(1):102\u2013104. https:\/\/doi.org\/10.1177\/0194599812437156","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"581_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/019459988509300202","volume":"93","author":"JW House","year":"1985","unstructured":"House JW, Brackmann DE (1985) Facial nerve grading system. Otolaryngol Head Neck Surg 93(2):146\u2013147. https:\/\/doi.org\/10.1177\/019459988509300202","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"10","key":"581_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1136\/jmedgenet-2017-104519","volume":"54","author":"D Halliday","year":"2017","unstructured":"Halliday D, Emmanouil B, Pretorius P, MacKeith S, Painter S, Tomkins H et al (2017) Genetic severity score predicts clinical phenotype in NF2. J Med Genet 54(10):657\u2013664. https:\/\/doi.org\/10.1136\/jmedgenet-2017-104519","journal-title":"J Med Genet"},{"issue":"1","key":"581_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13023-024-03512-3","volume":"20","author":"AC Lawson McLean","year":"2025","unstructured":"Lawson McLean AC, Loschner D, Farschtschi S, Dengler NF, Rosahl SK (2025) Clinical severity grading of NF2-related schwannomatosis. Orphanet J Rare Dis 20(1):4. https:\/\/doi.org\/10.1186\/s13023-024-03512-3","journal-title":"Orphanet J Rare Dis"},{"key":"581_CR27","unstructured":"Mokkink LB, Prinsen CA, Patrick DL, Alonso J, Bouter LM, De Vet HCW, Terwee CB (2019) COSMIN study design checklist for patient-reported outcome measurement instruments. Available from: https:\/\/www.cosmin.nl\/wp-content\/uploads\/COSMIN-study-designing-checklist_final.pdf."},{"key":"581_CR28","volume-title":"SF-36 physical and mental health summery scales: a user\u2019s manual","author":"JEKM Ware","year":"1994","unstructured":"Ware JEKM, Keller SD (1994) SF-36 physical and mental health summery scales: a user\u2019s manual. Health Assessment Lab, New England Medical Center, Boston"},{"key":"581_CR29","unstructured":"Foundation ER. EQ-5D-5L User Guide 2025 [Available from: https:\/\/euroqol.org\/information-and-support\/documentation\/user-guides\/"},{"key":"581_CR30","volume-title":"Straightforward statistics for the behavioral sciences","author":"JD Evans","year":"1996","unstructured":"Evans JD (1996) Straightforward statistics for the behavioral sciences. Thomson Brooks\/Cole Publishing Co, Belmont"},{"issue":"1","key":"581_CR31","doi-asserted-by":"publisher","first-page":"6934","DOI":"10.1038\/s41598-024-57401-7","volume":"14","author":"A Freier","year":"2024","unstructured":"Freier A, Lawson McLean AC, Loeschner D, Rosahl SK, Kruse J (2024) The impact of mental health on health-related quality of life in patients with NF2-related schwannomatosis. Sci Rep 14(1):6934. https:\/\/doi.org\/10.1038\/s41598-024-57401-7","journal-title":"Sci Rep"},{"issue":"5","key":"581_CR32","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00415-014-7303-1","volume":"261","author":"RE Ferner","year":"2014","unstructured":"Ferner RE, Shaw A, Evans DG, McAleer D, Halliday D, Parry A et al (2014) Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. J Neurol 261(5):963\u2013969. https:\/\/doi.org\/10.1007\/s00415-014-7303-1","journal-title":"J Neurol"},{"issue":"7","key":"581_CR33","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/neuonc\/noaa284","volume":"23","author":"C Forde","year":"2021","unstructured":"Forde C, King AT, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SR et al (2021) Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution. Neuro Oncol 23(7):1113\u20131124. https:\/\/doi.org\/10.1093\/neuonc\/noaa284","journal-title":"Neuro Oncol"},{"issue":"4","key":"581_CR34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ajmg.1320520411","volume":"52","author":"DM Parry","year":"1994","unstructured":"Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N (1994) Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52(4):450\u2013461. https:\/\/doi.org\/10.1002\/ajmg.1320520411","journal-title":"Am J Med Genet"},{"issue":"2","key":"581_CR35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139","volume":"152A","author":"DG Evans","year":"2010","unstructured":"Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM et al (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A(2):327\u2013332. https:\/\/doi.org\/10.1002\/ajmg.a.33139","journal-title":"Am J Med Genet A"},{"issue":"9","key":"581_CR36","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jmg-2024-110065","volume":"61","author":"C Forde","year":"2024","unstructured":"Forde C, Smith MJ, Burghel GJ, Bowers N, Roberts N, Lavin T et al (2024) NF2-related schwannomatosis and other schwannomatosis: an updated genetic and epidemiological study. J Med Genet 61(9):856\u2013860. https:\/\/doi.org\/10.1136\/jmg-2024-110065","journal-title":"J Med Genet"},{"key":"581_CR37","unstructured":"Numbeo. Quality of life index by country 2026 [Available from: https:\/\/www.numbeo.com\/quality-of-life\/rankings_by_country.jsp"},{"issue":"4","key":"581_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/j.1749-4486.2010.02176.x","volume":"35","author":"WJ Neary","year":"2010","unstructured":"Neary WJ, Hillier VF, Flute T, Stephens SD, Ramsden RT, Evans DG (2010) The relationship between patients\u2019 perception of the effects of neurofibromatosis type 2 and the domains of the short form-36. Clin Otolaryngol 35(4):291\u2013299. https:\/\/doi.org\/10.1111\/j.1749-4486.2010.02176.x","journal-title":"Clin Otolaryngol"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00581-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-026-00581-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-026-00581-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T22:02:26Z","timestamp":1781820146000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-026-00581-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1007\/s10689-026-00581-0","relation":{},"ISSN":["1573-7292"],"issn-type":[{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board of Leiden University Medical Center and conducted in accordance with the 2024 Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"66"}}